CSL Bull Positive on Outlook for Immunoglobulin

Dow Jones

Jul 22

2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. "Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency (PID/SID), key drivers of our industry volume growth forecast of 5.5% per annum through to 2030," MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. "However, benefits from immunoglobulin yield initiatives (Horizon 1 and 2) should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32," MS says. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

July 21, 2026 19:46 ET (23:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2653478115"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653478115\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653478115?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-22 07:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653478115","market":"sg","top_or_hot":-1,"title":"CSL Bull Positive on Outlook for Immunoglobulin","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. \"Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency (PID/SID), key drivers of our industry volume growth forecast of 5.5% per annum through to 2030,\" MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. \"However, benefits from immunoglobulin yield initiatives (Horizon 1 and 2) should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32,\" MS says. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 19:46 ET (23:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Bull Positive on Outlook for Immunoglobulin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Bull Positive on Outlook for Immunoglobulin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-22 07:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. \"Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency (PID/SID), key drivers of our industry volume growth forecast of 5.5% per annum through to 2030,\" MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. \"However, benefits from immunoglobulin yield initiatives (Horizon 1 and 2) should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32,\" MS says. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 21, 2026 19:46 ET (23:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1668664300.SGD","symbol_name":"Blackrock World Financials A2 SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653478115","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653478115","pubTimestamp":1784677560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. \"Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency , key drivers of our industry volume growth forecast of 5.5% per annum through to 2030,\" MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. \"However, benefits from immunoglobulin yield initiatives  should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32,\" MS says.  Dow Jones NewswiresJuly 21, 2026 19:46 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4534":"瑞士信贷持仓","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IAI":"iShares Dow Jones U.S. Broker De","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","KBWB":"银行ETF-PowerShares","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4086":"建筑产品","CSL.AU":"CSL LIMITED","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4516":"特朗普概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","BK7511":"ESG概念","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4588":"碎股","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","BK7067":"生物科技","LU0557290698.USD":"施罗德环球可持续增长基金","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2487616109.SGD":"JPM AMERICA EQUITY \"A\" (SGD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","CSL":"卡莱尔伙伴","LU0210528500.USD":"JPM AMERICA EQUITY \"A\" ACC","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU1548497426.USD":"安联环球人工智能AT Acc","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC"},"translate_title":"CSL 看好免疫球蛋白前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":0.9,"IAI":0.6,"KBWB":0.6},"content_text":"2346 GMT - Pharmaceutical company CSL keeps Morgan Stanley as a bull after reviewing the outlook for immunoglobulin and albumin. MS sees EPS falling 3% and 2% in FY 2026 and 2027, respectively, before rebounding to 8% growth annually over FY 2028-2030. MS stays positive on immunoglobulin's outlook. \"Over the medium to longer-term, we continue to see opportunities in primary and secondary immunodeficiency (PID/SID), key drivers of our industry volume growth forecast of 5.5% per annum through to 2030,\" MS says. In China, it expects regulatory changes to moderate volume growth and hurt selling prices. MS pares forecasts for immunoglobulin and albumin revenue growth. \"However, benefits from immunoglobulin yield initiatives (Horizon 1 and 2) should support margin expansion within CSL Behring, with our forecasts implying a gross margin of 54.5% by FY32,\" MS says. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 21, 2026 19:46 ET (23:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}